Financial Survey: Moolec Science (NASDAQ:MLEC) & Cartesian Growth Co. II (NASDAQ:RENE)

Moolec Science (NASDAQ:MLEC) and Cartesian Growth Co. II (NASDAQ:RENE) are both small-cap consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Moolec Science and Cartesian Growth Co. II’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-97.95%	-27.91%
Cartesian Growth Co. II	N/A	-51.08%	5.43%

Analyst Recommendations

This is a summary of recent ratings for Moolec Science and Cartesian Growth Co. II, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Cartesian Growth Co. II	0	0	0	0	0.00

Moolec Science presently has a consensus target price of $6.00, suggesting a potential upside of 625.51%. Given Moolec Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Moolec Science is more favorable than Cartesian Growth Co. II.

Volatility and Risk

Moolec Science has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Comparatively, Cartesian Growth Co. II has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 59.0% of Cartesian Growth Co. II shares are owned by institutional investors. 19.9% of Moolec Science shares are owned by insiders. Comparatively, 26.6% of Cartesian Growth Co. II shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Moolec Science and Cartesian Growth Co. II”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moolec Science	$5.62 million	5.66	-$7.31 million	($0.20)	-4.14
Cartesian Growth Co. II	N/A	N/A	$11.44 million	N/A	N/A

Cartesian Growth Co. II has lower revenue, but higher earnings than Moolec Science.

Summary

Cartesian Growth Co. II beats Moolec Science on 7 of the 11 factors compared between the two stocks.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.

About Cartesian Growth Co. II

Cartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.